Holen Sie sich die Stockscreener-App
5.15
6.70%
-0.37
Handel nachbörslich:
5.15
Schlusskurs vom Vortag:
$5.52
Offen:
$5.26
24-Stunden-Volumen:
238.54K
Relative Volume:
0.90
Marktkapitalisierung:
$290.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
-2.1281
EPS:
-2.42
Netto-Cashflow:
$-68.47M
1W Leistung:
-15.02%
1M Leistung:
-15.57%
6M Leistung:
-54.47%
1J Leistung:
-57.44%
1-Tages-Spanne:
$5.05
$5.35
1-Wochen-Bereich:
$5.05
$6.05
52-Wochen-Spanne:
$5.05
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Firmenname
Astria Therapeutics Inc
Sektor
Branche
Telefon
617-349-1971
Adresse
22 BOSTON WHARF ROAD, BOSTON
Vergleichen Sie ATXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
5.15 | 290.64M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | TD Cowen | Buy |
| 2023-03-28 | Eingeleitet | Evercore ISI | Outperform |
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
Teacher Retirement System of Texas Makes New Investment in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2025 - BioSpace
Astria Therapeutics Grants $235K Worth of Stock Options to Strategic New Hires - Stock Titan
Analysts Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $26.60 - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Purchased by Swiss National Bank - Defense World
Charles Schwab Investment Management Inc. Increases Stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) - Defense World
(ATXS) Investment Report - news.stocktradersdaily.com
Lifesci Capital Has Pessimistic View of ATXS FY2025 Earnings - Defense World
What is HC Wainwright’s Forecast for ATXS Q1 Earnings? - Defense World
Q1 EPS Forecast for Astria Therapeutics Decreased by Analyst - Defense World
Astria Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
(ATXS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Astria Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Astria Therapeutics price target raised to $28 from $27 at Wedbush - TipRanks
Wedbush Adjusts Price Target on Astria Therapeutics to $28 From $27, Keeps Outperform Rating - Marketscreener.com
Astria Therapeutics (NASDAQ:ATXS) Given Buy Rating at HC Wainwright - Defense World
Astria Therapeutics Advances Clinical Trials and Financials - TipRanks
Astria Therapeutics: Promising Developments and Strategic Advancements Justify Buy Rating - TipRanks
Astria Therapeutics, Inc. SEC 10-K Report - TradingView
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - BioSpace
Astria Therapeutics: Promising Pipeline and Strong Financials Drive Buy Rating - TipRanks
Preclinical data reported for Astria’s anti-OX40 monoclonal antibody - BioWorld Online
Astria Therapeutics posts marginally smaller-than-expected quarterly net loss per share - Marketscreener.com
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter
Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Acquired by New York State Common Retirement Fund - Defense World
Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.67 - Defense World
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
Astria Therapeutics Issues 87,450 Stock Options: What This Means for Shareholder Dilution - Stock Titan
Learn to Evaluate (ATXS) using the Charts - news.stocktradersdaily.com
Astria Therapeutics’ (ATXS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
HC Wainwright Reaffirms "Buy" Rating for Astria Therapeutics (NASDAQ:ATXS) - MarketBeat
Astria Therapeutics (ATXS) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Press Release From Business Wire: Astria Therapeutics, Inc. - UrduPoint News
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema - Business Wire
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference - Business Wire
Can Astria Therapeutics' Conference Appearance Signal New Developments in Allergic Disease Treatments? - Stock Titan
Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS) - Yahoo Finance
When the Price of (ATXS) Talks, People Listen - Stock Traders Daily
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress - Business Wire
Astria Therapeutics (NASDAQ:ATXS) Shares Pass Below Fifty Day Moving Average – What’s Next? - Defense World
Astria Therapeutics: A High-Conviction Bet On HAE - Seeking Alpha
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Price Target from Analysts - Defense World
How to Take Advantage of moves in (ATXS) - Stock Traders Daily
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.67 Consensus Target Price from Brokerages - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Now Covered by Analysts at JMP Securities - MarketBeat
Angioedema Pipeline 2024: Therapies Under Investigation, - openPR
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference - sharewise
Astria Therapeutics Unveils Strategic Employee Stock Options Worth $122K - Stock Titan
Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):